Cramer was left scratching his head in confusion when Skechers stock plunged dramatically on Friday.
The footwear company was considered among the hottest of the hot stocks, up more than 150 percent for the year, going into the quarter. Wall Street had gotten used to Skechers knocking it out of the park each time it reported earnings, so when the numbers were viewed by many as being disappointing, the stock lost 31 percent in a single session.
"Did Skechers truly blow it, or is the market overreacting because the expectations had simply gotten too high?" the "Mad Money" host asked.
Most important of all, Skechers maintained its guidance for the next quarter. Could this be a rare buying opportunity for the stock? To find out, Cramer spoke with the Skechers chief operating officer and chief financial officer, David Weinberg.
He said that he thinks this was an overreaction, stating, "Business is very good and continues to be very good."
Read More Skechers exec to Cramer: We will double in 5 years
Despite the rebound in biotechs on Friday, the group has taken a serious beating recently. However, when Cramer sees a privately held biotech that is doing exciting work, he wants to bring it to investors' attention before its approach spills over into the public market.
Intarcia Therapeutics is a privately held biotech that has developed a disruptive technology to treat Type 2 diabetes. One of the problems with diabetes drugs is that they need to be injected, and many patients do not take them regularly, if at all.
Intarcia has developed a two-inch rod that is implanted under the patient's skin and delivers a steady dose of Extenatide, a major Type 2 diabetes drug, over the course of an entire year as opposed to getting injections once a week.
The company announced positive Phase 3 trial results on its lead product back in August, and it acquired Phoundry Pharmaceuticals last month.
To learn more about the game-changing way that it treats diabetes, Cramer spoke to Intarcia Therapeutics Chairman and CEO Kurt Graves.
"Now that we have got this platform really figured out, what we are doing is we are building a pipeline of once a year medicines in big chronic diseases," Graves said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Amsurg Corp: "I'm staying away from the health care stocks in that cohort right now. Let's just let them come in. There's a lot of short sellers, we've got to wait."
McCormick & Co: "I've been recommending McCormick since the show began. I think that the stock remains a great buy."
Read MoreLightning Round: Stay away from this group now